This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200709-1387OCv1 177/7/720    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Wu, Q. Articles by Chu, H. W. PubMed PubMed Citation Articles by Wu, Q. Articles by Chu, H. W.

Toll-like Receptor 2 Down-regulation in Established Mouse Allergic Lungs Contributes to Decreased Mycoplasma Clearance

¹ Department of Medicine, National Jewish Medical and Research Center, and the University of Colorado Health Sciences Center, Denver, Colorado

Correspondence and requests for reprints should be addressed to Hong Wei Chu, M.D., National Jewish Medical and Research Center, 1400 Jackson Street, Room A639, Denver, CO 80206. E-mail: chuhw{at}njc.org

Rationale: Respiratory Mycoplasma pneumoniae (Mp) infection is involved in asthma pathobiology, but whether the established allergic airway inflammation compromises lung innate immunity and subsequently predisposes patients with asthma to Mp infection remains unknown.

Objectives: To test whether the established allergic airway inflammation compromises host innate immunity (e.g., Toll-like receptor 2 [TLR2]) to hinder the elimination of Mp from the lungs.

Methods: We used mouse models of ovalbumin (OVA)-induced allergic airway inflammation with an ensuing Mp infection, and cultures of mouse primary lung dendritic cells (DCs) and bone marrow–derived DCs.

Measurements and Main Results: Lung Mp clearance in allergic mice and TLR2 and IL-6 levels in lung cells, including DCs as well as cultured primary lung DCs and bone marrow–derived DCs, were assessed. The established OVA-induced allergic airway inflammation, or the prominent Th2 cytokines IL-4 and IL-13, inhibited TLR2 expression and IL-6 production in lung cells, including lung DCs, and eventually led to impaired host defense against Mp. Studies in IL-6 knockout mice indicated that IL-6 directly promoted Mp clearance from the lungs. IL-4– and IL-13–induced suppression of TLR2 was mediated by inhibiting nuclear factor-B activation through signal transducer and activator of transcription 6 (STAT6) signaling pathway.

Conclusions: The established OVA-induced allergic airway inflammation impairs TLR2 expression and host defense cytokine (e.g., IL-6) production, and subsequently delays lung bacterial clearance. This could offer novel therapeutic strategies to reinstate TLR2 activation by using TLR2 ligands and/or blocking IL-4 and IL-13 to ameliorate persisting respiratory bacterial infections in allergic lungs.

Key Words: asthma • lung • innate immunity • bacterial clearance

AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Mycoplasma pneumoniae infection is involved in asthma pathobiology, but whether the established allergic airway inflammation compromises lung innate immunity and subsequently predisposes patients with asthma to M. pneumoniae infection remains unknown. What This Study Adds to the Field Established allergic airway inflammation impairs lung, including dendritic cell–dependent, innate host defense, leading to delayed bacterial clearance from the lungs.

 

This article has been cited by other articles:

				K. Chmura, X. Bai, M. Nakamura, P. Kandasamy, M. McGibney, K. Kuronuma, H. Mitsuzawa, D. R. Voelker, and E. D. Chan Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L220 - L230. [Abstract] [Full Text] [PDF]